Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply by Authors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: sahu kk. Urol Pract. 2023 Oct 30:101097UPJ000000000000047102. doi: 10.1097/UPJ.0000000000000471.02. Online ahead of print. Urol Pract. 2023. PMID: 37903752 No abstract available.
Editorial Comment.
Sahu KK, Agarwal N. Sahu KK, et al. J Urol. 2023 Jan;209(1):130. doi: 10.1097/JU.0000000000002969.01. Epub 2023 Jan 1. J Urol. 2023. PMID: 36484444 No abstract available.
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: sahu kk. Prostate Cancer Prostatic Dis. 2023 Jul 17. doi: 10.1038/s41391-023-00696-w. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37460732
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: sahu kk. Prostate Cancer Prostatic Dis. 2023 Aug 24. doi: 10.1038/s41391-023-00706-x. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37620429 No abstract available.
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Mathew Thomas V, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: sahu kk. Urol Pract. 2024 Jan;11(1):32-35. doi: 10.1097/UPJ.0000000000000471. Epub 2023 Oct 30. Urol Pract. 2024. PMID: 37903742
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: sahu kk. Prostate. 2024 Jun;84(9):888-892. doi: 10.1002/pros.24696. Epub 2024 Apr 1. Prostate. 2024. PMID: 38561317
SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19.
Yu L, Abd Ghani MK, Aghemo A, Barh D, Bassetti M, Catena F, Gallo G, Gholamrezanezhad A, Kamal MA, Lal A, Sahu KK, Saxena SK, Elmore U, Rahimi F, Robba C, Song Y, Xia Z, Yu B. Yu L, et al. Among authors: sahu kk. Curr Med Chem. 2023;30(39):4390-4408. doi: 10.2174/0929867330666230330092725. Curr Med Chem. 2023. PMID: 36998130
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy.
Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U. Mathew Thomas V, et al. Among authors: sahu kk. Eur Urol Oncol. 2024 May 11:S2588-9311(24)00105-6. doi: 10.1016/j.euo.2024.04.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38735779
377 results